



## COVID-19: Interim Guidance for Health Care and Public Health Providers

### TREATMENT OF COVID-19 AND INFLUENZA

TABLE 4.1 CCHCS FORMULARY VACCINES FOR INFLUENZA 2020-2021 SEASON

<b>Table 4.1 CCHCS Formulary Vaccines for Influenza 2020-2021 Season</b> <i>Adapted from the CDPH and CDC Guidelines</i>			
<b>Vaccine</b>	<b>Delivery</b>	<b>Special Indications</b>	<b>Allergens</b>
Afluria Quadrivalent	IM	---	Egg protein, neomycin, polymyxin
Flucelvax Quadrivalent	IM	---	Egg protein (trace)
Flublok Quadrivalent	IM	Severe egg allergy	No allergens
Fluzone Trivalent High-Dose	IM	65 years or older	Egg protein

Excerpted from the Treatment of COVID-19 and Influenza section of the CCHCS Interim Guidance for Health Care and Public Health Providers: <https://cchcs.ca.gov/covid-19-interim-guidance/>

**\*\*Contraindications** include:

- History of a severe allergic reaction to the vaccine or any of its components (regardless of the component suspected of being responsible for the reaction). Information about vaccine components is located in package inserts from each manufacturer.
- Egg allergy is not a contraindication for receiving influenza vaccine; however, patients who have a history of a severe allergic reaction to egg (i.e., any symptoms other than hives) should be vaccinated in a medical setting under the supervision of a healthcare provider or with a vaccine formulation that does not contain egg protein.

**Precautions** include:

- Moderate or severe acute illness with or without fever.
- Guillain-Barré syndrome within 6 weeks following a previous dose of influenza vaccine.

For more information on allergies: [CDC on Influenza Vaccination](#) and [CDC on the Seasonal Flu Shot](#)

Revised 8/14/20